Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2020 16:55 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2020 07:05 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day
November 11, 2020 07:01 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting
November 09, 2020 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
November 05, 2020 16:06 ET
|
Calithera Biosciences, Inc.
--Calithera to Provide Corporate Update via Conference Call and Webcast at2:00 p.m. PT on November 5, 2020-- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences,...
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)
November 04, 2020 13:05 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel...
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2020 16:07 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280
November 02, 2020 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel...
Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
October 29, 2020 07:01 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference
October 07, 2020 08:08 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...